Background: Medical advancements have resulted in better survival and life expectancy among those with spina bifida, but a significantly increased risk of perinatal and postnatal mortality for individuals with spina bifida remains.
| BACKG ROU N D
Spina bifida is a common and major congenital disorder of the central nervous system characterised by incomplete or incorrect closure of the neural tube during the embryonic development. 1 Spina bifida affects over 150 000 births worldwide and contributes to significant disability and child mortality. 2 The observed prevalence of spina bifida varies globally and is largely influenced by differences in surveillance methods, prenatal diagnosis and elective termination policies, and folic acid fortification of staple foods in a given country or region. [3] [4] [5] Evidence from both randomised clinical trials and observational studies shows that many cases of spina bifida can be prevented by women taking 400-800 mcg/day of folic acid during preconception and early pregnancy. [6] [7] [8] [9] The United States Preventive Services Task Force (USPSTF) recommends that all women planning or capable of pregnancy take a daily supplement containing 0.4-0.8 mg (400-800 mcg) of folic acid. 10 Medical advancements since the 1960s, especially in developed countries, have resulted in better survival and life expectancy among those with spina bifida. 11 But even with improved medical care, studies show a significantly increased risk of perinatal and postnatal mortality for individuals with spina bifida compared to those without. 1, [12] [13] [14] [15] [16] [17] [18] Mortality associated with spina bifida is more frequent in countries with fewer resources and less health care access compared with their counterparts in high-income regions of the world. 1, 2, 4, 5 Few studies have been conducted that examined mortality associated with spina bifida, and most of them were conducted in developed countries. 15, 16, 19, 20 Wang et al conducted a population-based analysis examining the survival of children with spina bifida in New York State in the United States. In this large population-based study examining children born with spina bifida between years 1983 and 2006, the probability of survival was 93% up to age 7 days, 92% up to 1 month, 88% up to 1 year, 86% up to 5 years, and 82% up to 25 years. 16 Time trends in spina bifida survival are also not well examined globally; two studies from the United States and Canada showed an improvement in survival among cohorts born in later years compared with those born during the late 1970s and the early 1980s. 17, 20, 21 There are opportunities to study mortality among infants born with spina bifida utilising pooled data from large networks of established birth defects surveillance systems, which have a potential to link to death certificates or other administrative health data sets.
The primary objective of our study was to examine perinatal and infant and child mortality for those affected by spina bifida using data from multiple birth defects registries affiliated with the International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR) and examine temporal trends in mortality. As a secondary objective, we examined the total prevalence of spina bifida using data from participating programmes. We were also able to stratify by the availability of elective termination for fetal anomalies (ETOPFA) on perinatal and infant and child mortality.
| ME THODS

| Study design and setting
International Clearinghouse for Birth Defects Surveillance and Research was established in 1974 and is a voluntary non-profit organisation affiliated with the World Health Organization (http:// www.icbdsr.org/). As a consortium of birth defects surveillance and research programmes from around the world, ICBDSR investigates and aims to prevent birth defects and minimise any negative consequences associated with them. As of 2018, there are 42 birth defects surveillance programmes in ICBDSR, either population-based or hospital-based, of which 27 contribute data on an annual basis.
These registries provide aggregated data on children and fetuses affected with at least one of 39 different birth defects to ICBDSR for surveillance purposes (a list of all monitoring programmes and their surveillance attributes can be found at http://www.icbdsr.org/ wp-conte nt/annual_repor t/Repor t2014.pdf). Each programme also collects data on the total annual number of livebirths and stillbirths in their source population for each of the surveillance years to aid in prevalence estimation.
For the current analysis, each programme contributed data for the longest period available, and in general, this period included the year the surveillance programme started until year 2015 or last year of the surveillance (Figure 1 ). We used data from 24 ICBDSR member registries or programmes, representing 18 countries in Asia, Europe, North America, and South America. Programmes were eligible to participate in the study if they collected data on both spina bifida prevalence and mortality among infants born with spina bifida. For each programme in our study, we examined indicators describing the type of registry (population-based vs. hospital-based systems), coverage, ascertainment period, stillbirth definition, ETOPFA allowed and availability of prenatal screening services (Table 1) . Each programme has local procedures for ethics approval, and because this study was done using aggregated data, no additional ethics committee approval was required. 
| Spina bifida-Case definition
Synopsis
Study question
To examine perinatal and infant and child mortality and its trends for those affected with spina bifida.
What is already known
Medical advancements have resulted in better survival and life expectancy among those with spina bifida, but a significantly increased risk of perinatal and infant and child mortality remains.
What this study adds
Our multi-country study showed perinatal and infant and child mortality is a major concern for those with spina bifida. The overall first-week mortality proportion was lower in programmes with policies that allowed elective terminations of pregnancy for fetal anomalies compared with those that did not. The proportion of perinatal and infant and child deaths were higher among spina bifida cases with co-occurring unrelated major anomalies or genetic syndromes compared with those with isolated spina bifida. co-occurring unrelated major birth defects. The definition of MCA included spina bifida co-occurring with one or more unrelated major anomalies. A case was defined as 'syndromic' when the spina bifida was part of a genetic disorder or a recognised syndrome.
| Mortality
Information on mortality was based on several follow-up methods as applied by the surveillance programmes, including follow-up until discharge from the hospital after birth, active or passive follow-up of the children by clinicians or registry staff, or follow-up by linking to administrative databases such as death records or other health care databases. Programmes could use more than one follow-up method.
In Table 2 , we present the method of follow-up that was applied in each programme. In our analysis, we examined mortality at different ages, including up to the first day of life, day 2-6 (early neonatal), day 7-27 (late neonatal), day 28-1 year (infant), 1-4 years (under five), and ≥5 years of age.
| Statistical analysis
We report results primarily per individual programme, and not as a pooled analysis, because some programmes contributed considerably more cases than others, and because our main goal was to examine variations across individual programmes and countries.
For each programme, we calculated total prevalence of spina bifida as the total number of cases with spina bifida (livebirths + stillbirths +ETOPFA for spina bifida) divided by the total number of births (livebirths + stillbirths) in a specified time period. We estimated prevalence and 95% confidence interval for the prevalence estimate using the Poisson approximation of binomial distribution.
We did not include ETOPFA in the denominator of the prevalence formula because of lack of data on the total number of terminations for each programme. We estimated the proportion of spina bifida-affected pregnancies resulting in livebirths, stillbirths, and ETOPFA.
Among liveborn spina bifida cases, we calculated age-specific mortality as number of deaths among liveborn cases divided by total number of liveborn cases with spina bifida, at different ages (day of birth, days 2-6, days 7-27, days 28-1 year, 1-4 years, and 5 years or greater), depending on programmes' availability ( Table 2 ). We ex- (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) , and so on); for some programmes, the first and last period may be fewer than 5 years.
We did not report results by single years or for programmes that had fewer than 5 cases. 
| RE SULTS
| Programme characteristics
A total of 24 ICBDSR member programmes with birth defects registries representing 18 countries contributed data for a part or entire time period between years 1974 and 2015 examined in our analysis ( Figure 1 ). Sixteen of the 24 registries were population-based, with regional (n = 10), statewide (n = 3), or national (n = 3) coverage.
The maximum age of ascertainment for birth defects varied by programme; however, most cases of spina bifida can be easily identified at birth. Criteria to define stillbirths also varied. ETOPFA was not 
| Prevalence and pregnancy outcome
Since most programmes provided data for surveillance years 2001-2012 (83% of programmes presented data on 2001, increasing to more than 95% of programmes in 2012), we elected to focus our analysis on this time interval. This allowed comparison of results between programmes. In Table 3 , we present programme-specific spina bifida prevalence per 10 000 total births and the pregnancy outcome. period , are presented in Table S1 . The total number of births covered by all programmes was 28 213 327 (including livebirths and stillbirths), and the total number of spina bifida cases equalled to 14 159. Thus, the prevalence of spina bifida in our study was estimated to be 5.0 per 10 000 total births (95% CI 4.9, 5.1).
| Mortality
The overall first-week mortality (years 2001-2012) proportion was 6.9% (95% CI 6.3%, 7.7%) ( Table 4 ). The first-week mortality proportion was lower in programmes where ETOPFA was available.
When taking isolated and complex cases together, the majority of deaths occurring during the first week of life were reported to have been during the first day of life. However, in Malta (based on 1 case),
Northern Netherlands, and Israel, the majority of spina bifida deaths occurred after the first day. Most (~80%) deaths occurred within the first 28 days of life (neonatal period).
A total of 17 programmes provided data on additional birth defects co-occurring with spina bifida. Since the number of spina bifida cases with a syndromic aetiology was very small, we pooled them with the MCA cases in the analyses. On average, 68% presented as isolated and 32% as MCA or as part of a genetic syndrome ( Table 5 ). The distribution varied by programme; in Israel and Mexico-RYVEMCE, more than 90% of spina bifida cases were described as isolated, whereas in Italy-Lombardy and in South America-ECLAMC, 53% and 51% were described as isolated, respectively. In Europe, where ETOPFA is allowed and common, ETOPFA proportion was similar between isolated and MCA/syndromic cases.
Among all programmes, the proportion of first-day and first-week mortality was higher in MCA/syndromic cases compared with isolated cases ( Table 5 ).
Only 10 programmes, from Europe and North America, provided information on long-term mortality (over age 1 year) using linkage to vital records. These programmes were Czech Republic, Italy-Lombardy, Malta-MCAR, Sweden, Italy-Tuscany, UK-Wales, USA-Arkansas, USA-Atlanta, USA-Texas, and USA-Utah. In Europe, survival up to age 1-4 years was 90%-96%, and in North American programmes, the survival was similar, at 86%-96% ( Figure 2 ).
Trends in ETOPFA, stillbirths, and first-week mortality in livebirths affected with spina bifida from registries contributing to the ICBDSR are presented in Figure S1 . Looking at pooled 5-year, programme-specific trends in mortality, we found that in most European programmes an increase in ETOPFA proportion was observed over time, which was accompanied by a decrease in stillbirths and first-
week mortality (eg Czech Republic, France-Paris, Germany-Saxony Anhalt, Italy, Northern Netherlands, Spain, and Sweden). In the Slovak Republic, the proportion of ETOPFA, stillbirth, and first-week mortality declined in the most recent study period (2011) (2012) (2013) (2014) . In UK-Wales, a decline in ETOPFA was also observed but with stable stillbirth and first-week mortality proportions. In the United States, a decreasing trend in the ETOPFA proportion was observed during the same period, with a relatively stable or decreasing stillbirth and first-week mortality proportions (except for USA-Texas, where an increase in first-week mortality was observed). In Mexico-RYVMCE, a decreasing trend in both the ETOPFA proportion and the stillbirth proportions were observed.
| COMMENT
| Principal findings
This is the first multi-country, multi-registry study that provides estimates of prevalence, perinatal and infant and child mortality, and mortality trends among those born with spina bifida using data from 24 birth defects programmes in 18 countries affiliated with the ICBDSR. Our findings confirm that a substantial propor- 
| Strengths of the study
Our study was the first to examine perinatal and infant child mortality among those born with spina bifida in a diverse set of populations using multi-registry, multi-country data. International Clearinghouse for Birth Defects Surveillance and Research programmes have quality control protocols to enhance case specificity for spina bifida, while tracking cases from multiple data sources. We were able to examine all birth outcomes, including stillbirths and ETOPFA.
Information on whether infants with spina bifida had additional birth defects was available for most programmes. Mortality outcomes were examined by age. Most programmes had information on mortality during the first week of life, and we could compare findings between programmes. Programmes provided information on existing policies on ETOPFA, which allowed us to compare findings by ETOPFA policies. Mortality outcomes were pooled by isolated and non-isolated cases of spina bifida.
| Limitations of the data
There were several limitations in our study. First, programmes that contributed data were not homogenous in methods; and the surveillance periods varied. We did not have individual-level data. We may have missed some cases as programmes may not have captured all stillbirths and ETOPFA cases. Accuracy of mortality outcomes, and age at death, cannot be confirmed. Data linkages with death certificates were not uniform across all programmes. We were unable to examine temporal trends in mortality for programmes that provided data for short durations (ie <5 years). There may have been deaths that could not be tracked due to limitations in administrative data linkages, or if they occurred outside the programme surveillance area.
| Interpretation
The average prevalence of spina bifida (including all cases) in our analysis, using data from 24 programmes reporting to ICBDSR, 
Survival in live births -North America
USA-Arkansas
USA-Atlanta
USA-Texas
USA-Utah lesion severity, and other aforementioned factors on mortality associated with spina bifida, as data were unavailable and beyond the scope of our current analysis.
We noted an increasing trend in ETOPFA for spina bifida in European programmes, with a concomitant decrease in stillbirths and first-week mortality proportions. A retrospective cohort study from the Netherlands examining the impact of introduction of the mid-trimester scan during the year 2007 on pregnancy outcome of spina bifida cases diagnosed pre-or postnatally reported that pregnancies that previously might have ended in a perinatal loss are now terminated, while pregnancies with a relatively good prognosis are frequently not terminated; the overall number of liveborn children with spina bifida has not changed significantly. 27 
| CON CLUS IONS
Data from 24 programmes provided a first summary of spina bifida-associated perinatal and infant and child mortality and their trends. In the many countries that contributed data for our analysis, mortality among those affected with spina bifida is a major concern, especially during the first day and first week of life. 
ACK N OWLED G EM ENTS
We thank each ICBDSR member programme's staff for providing information on the characteristics of their programme and data on spina bifida case status, and for conducting linkages between birth defects registries and administrative databases to assess mortality outcomes.
Disclaimer The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
O RCI D
Marian K. Bakker https://orcid.org/0000-0001-5098-6400
